skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

開発パイプラインの情報収集に世界基準のデータベースを

Pharmaprojects | Pharma intelligence

インフォーマ・ファーマインテリジェンスでは、臨床試験や治験責任医師、治験施設、開発品に関する幅広い情報をワンストップで提供しています。

リアルタイムで世界中の臨床試験情報を更新するTrialtroveや、治験責任医師と治験施設のデータベースであるSitetroveに加えて、Pharmaprojects(ファーマプロジェクツ)では1980年以降の開発パイプライン情報をトラッキングしています(*TrialtroveとSitetroveは2015年までCitelineという製品名でご提供していました)


Pharmaprojectsが収録する主な情報の例

  • 開発企業、ライセンス企業
  • 適応症
  • 開発段階
  • ターゲット、作用機序
  • 投与経路

 

Phramaprojectsの情報は弊社アナリストによる精査ののちデータベースに収録されます。また、下記に示すように、インフォーマ・ファーマインテリジェンス独自のインデックスや分類を追加することで、ノイズが少ない、ニーズに合ったきめ細かい検索が可能となります。アナリストによるこのような編集プロセスを経て、幅広いソースから集めた「情報」は、御社に競争力をもたらす「知識」へと変換されます。

  • 薬効分類
  • 希少疾患
  • ドラッグデリバリーシステム
  • 希少疾病用医薬品指定
  • 迅速承認制度


Phramaprojectsを活用することで、下記のような疑問に答えることができます

  • 前臨床もしくは臨床段階で競合する企業・医薬品は?
  • 有効な治療法が確立されていない領域で、もっとも投資効率が高いものは?
  • 世界的に承認されて販売されている医薬品に関して、まだ上市されていない国は?
  • 開発に失敗した要因は何か?
  • ライセンスインできる医薬品候補化合物は?
  • 特定の疾患領域での開発動向を参考にして、自社品の優先順位を見直せないか?
  • 医薬品開発において特定の疾患領域での失敗確率は?
  • 中期的に開発戦略に影響を与えそうな競合薬は?・

 

インフォーマセミナー講演動画『世界の医薬品の臨床研究・開発をめぐる最新動向』
Pharmaprojectsのシニアディレクター・Ian Lloydが、毎年恒例の業界年次レポートPharma R&D Annual Reviewに基づいて講演を行いました(2018/02/21・東京)

このサービスの特徴

無料の最新記事&レポート

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    In Vivo's Rising Leaders List

    In Vivo brings you another exclusive look into the future of biopharma, medtech and healthtech with our new article pack that features interviews with rising leaders and established executives, all sharing their insight. Download your free pack for a view of how today’s rising leaders are shaping the life sciences industries of tomorrow.

    Topic Leadership medtech

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    In Vivo's 30 Rising Leaders of 2020

    Find out who is coming through the ranks of biopharma, medtech and healthtech organizations with In Vivo’s infographic, “30 Rising Leaders of 2020”. Your free infographic provides a snapshot view of the entrepreneurs and innovators who are moving their industries forward with creative thinking and new technologies.

    Topic Leadership medtech

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    COVID-19 Pandemic Accelerates Shift Toward Virtual Trials

    As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.

    Topic Coronavirus

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Bacteria Are Blind To Politics

    Bacteria Are Blind To Politics

    Evan Loh, CEO of infectious disease drug developer Paratek Pharmaceuticals, explains why eliminating the DISARM ACT, which focused on finding solutions against antimicrobial resistance, from the new coronavirus aid package is a shortsighted move by US congress. 

    Topic Coronavirus

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Drug Distributors Mitigate Coronavirus

    For most patients, drug distributors – companies that provide, control and manage drug supplies – operate as an unseen but critical link in the supply chain. In the context of a global pandemic, however, drug distributors play an even bigger role in helping to ensure that pharmacies, health systems and ultimately patients have access to essential medicines.

    Topic Coronavirus

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    FDA Emphasizes Clinical Trial Flexibility During Coronavirus Pandemic

    FDA Emphasizes Clinical Trial Flexibility During Coronavirus Pandemic

    FDA guidance updated in mid-April offered workarounds for trial sponsors attempting to conduct clinical studies in a time of travel limitations, staffing changes and heightened patient safety issues. For trials involving complex products and administration, such as cell and gene therapies, sponsors must determine whether modified protocols can still maintain trial integrity. If not, it may be time to press pause. 

    Topic Coronavirus FDA

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

    trial-diversity

    The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.

    Topic Clinical Trials

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    In Vivo Deal Making Article Pack

    In Vivo Deal Making Article Pack

    Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Scrip: 世界の医療用医薬品&製薬産業に関するニ...

    Webinar: Is Biopharma Fit For the New Decade?

    Webinar: Is Biopharma Fit For the New Decade?

    Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.

    Topic Cell and gene therapy Policy and regulation

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Fact File: Coronavirus Pipeline And Corporate Updates

    The coronavirus outbreak is at a tipping point, after which its development into a global pandemic may be unstoppable. Companies large and small have mobilized in the fight against the disease bringing new and repurposed treatment options into development and preparing their business for the unsteady months ahead.

    Topic Coronavirus

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Regular Acceptance Of Simulation Studies More Likely In 2020s

    Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

    Topic biopharmaceutical

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    A Tale Of Two Pipelines

    Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

    Topic Cancer Research

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

    The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Bayer US Pharmaceuticals' Sebastian Guth: Designs On A New Decade

    Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Outlook 2020 Report

    Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.

医薬品産業専門のジャーナリスト&アナリスト

製品説明を兼ねた無料デモ&お問い合わせ

専任スタッフによる詳しい説明を兼ねた無料デモンストレーションを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。